canakinumab
Selected indexed studies
- Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. (N Engl J Med, 2018) [PMID:29768139]
- Canakinumab. (MAbs, 2010) [PMID:20065636]
- Canakinumab for secondary prevention of coronary artery disease. (Future Cardiol, 2021) [PMID:33533289]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. (2018) pubmed
- Canakinumab. (2010) pubmed
- Canakinumab for secondary prevention of coronary artery disease. (2021) pubmed
- Canakinumab for the treatment of adult-onset Still's disease. (2020) pubmed
- Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. (2012) pubmed
- Canakinumab for the treatment of hyperimmunoglobulin D syndrome. (2019) pubmed
- Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. (2017) pubmed
- Canakinumab in gout. (2012) pubmed
- Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy. (2019) pubmed
- Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. (2018) pubmed